Literature DB >> 21722807

Flow cytometry-based pharmacodynamic monitoring after organ transplantation.

Maja-Theresa Dieterlen1, Katja Eberhardt, Attila Tarnok, Hartmuth B Bittner, Markus J Barten.   

Abstract

Conventional therapeutic drug monitoring based on measuring immunosupressive drug concentrations in blood is important in the clinical management of immunosuppressive therapy in transplantation medicine. Since rejection or infection occurs at irregular drug concentrations immunosuppressive drug therapy is often empiric and prophylactic in nature. In addition, blood immunosuppressant levels are only indirect predictors of the pharmacologic effects on immune cells, because the genetic heterogeneity the immune systems of transplant recipients are not equally sensitive to drug effects. Therefore, therapeutic drug monitoring requires the application of reliable and effective methods to study the pharmacodynamic variability by direct measurements of drug effects on immune cell functions. Flow cytometry offers a multiplicity of quantitative analysis possibilities, from detection of phosphorylated molecules up to complex multicolor analysis of whole blood samples. A large spectrum of flow cytometry-based applications for pharmacodynamic monitoring is available and allows detection and analysis of diverse function of T cells and dendritic cell subsets. By combining several assays, it is possible to generate a broad picture of the immune status of every single transplanted recipient. Furthermore, it is even possible to differentiate between synergistic and antagonistic pharmacodynamic effects of immunosuppressive drug combination therapy in vitro and to predict the pharmacodynamic drug effects in transplanted recipients. Such a pharmacodynamic drug monitoring may offer the opportunity to complete conventional therapeutic drug monitoring and, therefore, to tailor immunosuppressive therapy more individually.
Copyright © 2011 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21722807     DOI: 10.1016/B978-0-12-385493-3.00011-5

Source DB:  PubMed          Journal:  Methods Cell Biol        ISSN: 0091-679X            Impact factor:   1.441


  5 in total

1.  Impact of recent innovations in the use of mass cytometry in support of drug development.

Authors:  Ala F Nassar; Hideki Ogura; Adam V Wisnewski
Journal:  Drug Discov Today       Date:  2015-06-16       Impact factor: 7.851

Review 2.  Immune monitoring as prerequisite for transplantation tolerance trials.

Authors:  K Behnam Sani; B Sawitzki
Journal:  Clin Exp Immunol       Date:  2017-06-23       Impact factor: 4.330

3.  Blood dendritic cell levels associated with impaired IL-12 production and T-cell deficiency in patients with kidney disease: implications for post-transplant viral infections.

Authors:  Ping Chen; Qianmei Sun; Yanfei Huang; Mohamed G Atta; Sharon Turban; Dorry L Segev; Kieren A Marr; Fizza F Naqvi; Nada Alachkar; Edward S Kraus; Karl L Womer
Journal:  Transpl Int       Date:  2014-08-20       Impact factor: 3.782

Review 4.  Immunologic monitoring in kidney transplant recipients.

Authors:  Natavudh Townamchai; Kassem Safa; Anil Chandraker
Journal:  Kidney Res Clin Pract       Date:  2013-05-29

5.  Assessment of Immunological Biomarkers in the First Year after Heart Transplantation.

Authors:  Maja-Theresa Dieterlen; Katja John; Hartmuth B Bittner; Meinhard Mende; Attila Tarnok; Friedrich W Mohr; Markus J Barten
Journal:  Dis Markers       Date:  2015-09-30       Impact factor: 3.434

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.